ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more
ReShape Lifesciences Inc (RSLS) - Total Assets
Latest total assets as of June 2025: $9.03 Million USD
Based on the latest financial reports, ReShape Lifesciences Inc (RSLS) holds total assets worth $9.03 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ReShape Lifesciences Inc - Total Assets Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ReShape Lifesciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
ReShape Lifesciences Inc's total assets of $9.03 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $987.00K | 20.6% |
| Inventory | $2.46 Million | 51.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how ReShape Lifesciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ReShape Lifesciences Inc's current assets represent 95.7% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2024, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 51.3% of total assets.
ReShape Lifesciences Inc Competitors by Total Assets
Key competitors of ReShape Lifesciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
ReShape Lifesciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - ReShape Lifesciences Inc generates 1.67x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - ReShape Lifesciences Inc is currently not profitable relative to its asset base.
ReShape Lifesciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.77 | 1.90 | 0.57 |
| Quick Ratio | 1.97 | 0.89 | 0.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.66 Million | $ 2.89 Million | $ -6.12 Million |
ReShape Lifesciences Inc - Advanced Valuation Insights
This section examines the relationship between ReShape Lifesciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.42 |
| Latest Market Cap to Assets Ratio | 0.60 |
| Asset Growth Rate (YoY) | -55.1% |
| Total Assets | $4.79 Million |
| Market Capitalization | $2.89 Million USD |
Valuation Analysis
Below Book Valuation: The market values ReShape Lifesciences Inc's assets below their book value (0.60 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ReShape Lifesciences Inc's assets decreased by 55.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ReShape Lifesciences Inc (2003–2024)
The table below shows the annual total assets of ReShape Lifesciences Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.79 Million | -55.05% |
| 2023-12-31 | $10.66 Million | -4.30% |
| 2022-12-31 | $11.14 Million | -79.46% |
| 2021-12-31 | $54.26 Million | +46.40% |
| 2020-12-31 | $37.06 Million | -6.54% |
| 2019-12-31 | $39.66 Million | -14.30% |
| 2018-12-31 | $46.27 Million | -47.84% |
| 2017-12-31 | $88.70 Million | +1159.84% |
| 2016-12-31 | $7.04 Million | -39.23% |
| 2015-12-31 | $11.59 Million | -19.46% |
| 2014-12-31 | $14.39 Million | -45.48% |
| 2013-12-31 | $26.39 Million | +1.12% |
| 2012-12-31 | $26.10 Million | -19.67% |
| 2011-12-31 | $32.49 Million | -16.03% |
| 2010-12-31 | $38.69 Million | +138.60% |
| 2009-12-31 | $16.21 Million | -42.66% |
| 2008-12-31 | $28.28 Million | -52.11% |
| 2007-12-31 | $59.05 Million | +63.74% |
| 2006-12-31 | $36.06 Million | +211.95% |
| 2005-12-31 | $11.56 Million | +1512.39% |
| 2003-12-31 | $717.00K | -- |